Related Experiment Video
Updated: Jan 15, 2026

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Ferula asafoetida oleo-gum resin alleviates dyspepsia symptoms through modulation of microbiome-gut-brain axis: A
Syam Das S1, Veena Rm2, P A Aneesa3,4
1R&D Centre, Akay Natural Ingredients, Cochin, Kerala, India.
Background:
Functional dyspepsia (FD) is a prevalent gut-brain interaction disorder that adversely affects cognitive function. Current treatment options offer limited efficacy and are often associated with undesirable side effects. Hence, in this study, we evaluated the efficacy of a food-grade, self-emulsifying hydrogel formulation of Ferula asafoetida oleo-gum resin (ASF) in improving dyspepsia symptoms, cognitive function, sleep quality, and gut microbiota in individuals with FD symptoms.
Methods:
A randomized, double-blind, placebo-controlled trial was conducted with 62 participants diagnosed with FD symptoms. Subjects received 250 mg/d of ASF or placebo for 14 days. Outcome measures included the Leuven Postprandial Distress Scale, choice reaction time test, Bergen Insomnia Scale (BIS), Bristol Stool Form Scale, and gut microbiome profiling.
Results:
ASF treatment showed a significant time, treatment, and treatment × time effect for early satiety, bloating, and heart burn (P < .05). Further analysis of Leuven Postprandial Distress Scale data by Mann-Whitney U test provided the influence of ASF on days 1, 3, 7, and 14 which indicated a progressive improvement in the number of positive responders, especially for bloating, early satiety, and postprandial fullness (P < .05). ASF also significantly modulated the gut microbiota by decreasing the Firmicutes-to-Bacteroidetes ratio (71.9%; P < .001), enhancing alpha diversity (P < .05), enriching beneficial genera (e.g., Bacteroides, Prevotella), and reducing harmful taxa (e.g., Escherichia, Clostridia). Further, ASF demonstrated improvements in digestion and reduced constipation as indicated by the Bristol Stool Form Scale, with type 1 stools decreasing from 65% to 18% and type 2 from 35% to 7% by day 14. Neurocognitive assessments showed improved attention and focus (44% reduction in reaction time, P < .001), while BIS results indicated better sleep quality (ΔBIS = 10.89 ± 3.23, P < .001) on day 14.
Conclusion:
ASF demonstrated significant modulation of the microbiome-gut-brain axis, resulting in reduced dyspepsia symptom severity, enhanced cognitive performance, improved sleep quality, and better digestive outcomes. These findings support the potential of ASF as a safe and effective dietary supplement for gut and cognitive health in individuals with FD.
More Related Videos
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
07:33Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
Published on: July 6, 2015
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...